Jérôme Cornillon
Jérôme Cornillon is an expert in Hematology at Centre Hospitalier Universitaire de Saint-Etienne (France). As of October 2026, ScienceLeadR ranks Jérôme Cornillon in the top 1% of experts worldwide for Stem Cell Transplantation and Cell Transplantation. Jérôme Cornillon has authored 239 publications, the most recent in 2026, and is an investigator in 40 clinical trials, 19 of them ongoing. SLR score: 1,042 (community average: 125). How the SLR is computed.
LeadR Profile
Hematology
Subspecialties: Oncology - Transplantation - Surgery
Main Topics
Publications and Clinical Studies
Profile data updated on
Expert Rankings
Top experts on the MeSH terms this expert works on
Organizations
Career arc: 2004 - 2026
Number : 239
Citations
Main journals
Best Journals
Breakdown by type
Click a legend label to hide or show it in the chart.
Latest Publications
5 most recent indexed articles
Source: Pubmed
Clinical Studies 40
Synthesis
By phase:
By status:
By type:
By Monocentric/Multicentric:
Ongoing Clinical Trials
19 ongoing trials started since 2021, where this expert is an investigator
Source: ClinicalTrials
| Study | Phase | Status | Start |
|---|---|---|---|
| Study comparing thymoglobulin to grafalon two treatments used to prevent graft versus host disease in elderly patients with acute myeloid leukemia or myelodysplastic syndrome and receiving an allogeneic stem cell transplantation with an unrelated matched donor after a reduced intensity conditioning regimen 2023-504555-27-00 — cells, myelodysplastic syndromes, microscopy, electron, scanning transmission, hematopoietic stem cell transplantation, leukemia, stem cells, leukemia, myeloid, acute, aged, leukemia, myeloid, graft vs host disease, transplants, therapeutics, cell transplantation, conditioning, psychological, stem cell transplantation, hematopoietic stem cells, transplantation | Phase 3 | Recruiting | 2023 |
| FLUCLORIC Randomized multicentric Phase III study comparing the efficacy of two reduced intensity conditioning regimens (clofarabine busulfan versus fludarabine busulfan) in adults with acute myeloid leukemia and eligible to allogeneic stem cell transplantation a SFGM TC study 2022-502019-12-00 — cells, microscopy, electron, scanning transmission, clofarabine, leukemia, stem cells, leukemia, myeloid, acute, leukemia, myeloid, cell transplantation, conditioning, psychological, stem cell transplantation, busulfan, transplantation | Phase 3 | Recruiting | 2023 |
| A Trial to Learn if Odronextamab Combined with Chemotherapy is Safe and Well Tolerated and How Well it Works Compared to Rituximab Combined with Chemotherapy for Adult Participants with Follicular Lymphoma 2022-502113-28-00 — lymphoma, follicular, safety, lymphoma, drug therapy, rituximab, chemotherapy | Phase 3 | Recruiting | 2024 |
| A multi center randomized double blinded phase IIb trial evaluating oral pooled fecal microbiotherapy MaaT033 to prevent allogeneic hematopoietic cell transplantation complications 2022-501831-18-00 — cells, hematologic neoplasms, multiple chronic conditions, cell transplantation, transplantation | Phase 2 | Recruiting | 2023 |
| Efficacy of an Empirical Treatment With Amoxicillin clavulanate (AC) Compared to the Combination Amoxicillin clavulanate and Ciprofloxacin (AC C) in the Outpatient Care of Chemotherapy induced Fever in Adult Haematology Patients NCT07483736 — febrile neutropenia, amoxicillin-potassium clavulanate combination, ciprofloxacin, amoxicillin, neutropenia, drug therapy, drug-related side effects and adverse reactions, ambulatory care, therapeutics, outpatients, bacteria, chemotherapy | Phase 3 | Not yet recruiting | 2026 |
LeadR Networks
Main global connection map